BioSpace News Archive

Pepscan is solely responsible for production of clinical neoantigen peptides, tailored to tumors of individual patients.

Array BioPharma Inc. announced that it will present updated data from the combination of BRAFTOVI®, a BRAF inhibitor, MEKTOVI®, a MEK inhibitor, and ERBITUX®, an anti-EGFR antibody, in patients with advanced BRAFV600E-mutant metastatic colorectal cancer, following one or two lines of therapy.

With the Start of Hurricane Season, Dedicated Communications Platform Will Help Ensure Patients Maintain Access to Life-Sustaining Dialysis Treatment During Natural Disasters [25-June-2019] WALTHAM, Mass. , June 25, 2019 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation’s leading renal care company, is approved to join FirstNet – a new communi

Bausch Health Companies Inc. announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash generated from operations.

Following the successful launch of Oxervate, the first-in-class recombinant human nerve growth factor (rhNGF) for treatment of neurotrophic keratitis (NK), Dompé embarks on a new clinical trial program to further investigate the relevance of treatment with rhNGF in Dry Eye Disease (DED).

Eisai Inc. announced results from its FREEDOM Study, a Phase III open-label study conducted in Japan and South Korea evaluating the efficacy and safety of FYCOMPA® CIII as monotherapy in new onset or untreated patients with partial-onset seizures.

It will be the first time interim results from the global, prospective verITI-8 study of rFVIIIFc for first-time ITI will be presented.

Aspen RxHealth’s platform connects patients to community pharmacists, optimizing patient interactions

Genentech alumna to lead Ambys’ business strategy and growth initiatives to support company’s focus on pioneering regenerative medicine for advanced liver diseases

Highlights How the Board is Distorting the Truth, Mischaracterizing the Company’s Current Dire State and Misleading Stockholders in an Attempt to Preserve the Troubling Status Quo